Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.22 | -5.86666666667 | 3.75 | 3.75 | 3.23 | 433451 | 3.4449574 | CS |
4 | -0.42 | -10.6329113924 | 3.95 | 4.27 | 3.23 | 606760 | 3.85205976 | CS |
12 | -4.47 | -55.875 | 8 | 9.5 | 3.01 | 825457 | 5.82230853 | CS |
26 | -6.76 | -65.6948493683 | 10.29 | 10.37 | 3.01 | 674184 | 6.54552935 | CS |
52 | -0.58 | -14.1119221411 | 4.11 | 13.68 | 3.01 | 622496 | 7.65483703 | CS |
156 | -5.48 | -60.8213096559 | 9.01 | 13.68 | 1.53 | 335056 | 6.21442405 | CS |
260 | -8.47 | -70.5833333333 | 12 | 25.87 | 1.53 | 243461 | 6.95454113 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約